[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.v71.3
|
[2] |
XIA C F, DONG X S, LI H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J, 2022, 135(5): 584-590.
doi: 10.1097/CM9.0000000000002108
|
[3] |
BOILEAU J F, POIRIER B, BASIK M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study[J]. J Clin Oncol, 2015, 33(3): 258-264.
|
[4] |
KUEHN T, BAUERFEIND I, FEHM T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol, 2013, 14(7): 609-618.
doi: 10.1016/S1470-2045(13)70166-9
pmid: 23683750
|
[5] |
CAUDLE A S, YANG W T, KRISHNAMURTHY S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection[J]. J Clin Oncol, 2016, 34(10): 1072-1078.
doi: 10.1200/JCO.2015.64.0094
pmid: 26811528
|
[6] |
WU S Y, LI J W, WANG Y J, et al. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study[J]. Int J Surg, 2023, 109(7): 1863-1870.
|
[7] |
HARTMANN L C, SELLERS T A, SCHAID D J, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers[J]. J Natl Cancer Inst, 2001, 93(21): 1633-1637.
doi: 10.1093/jnci/93.21.1633
|
[8] |
SUN J, CHU F T, PAN J N, et al. BRCA-CRisk: a contralateral breast cancer risk prediction model for BRCA carriers[J]. J Clin Oncol, 2023, 41(5): 991-999.
doi: 10.1200/JCO.22.00833
|
[9] |
LI X, YANG C Y, WAN H, et al. Discovery and development of pyrotinib: a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer[J]. Eur J Pharm Sci, 2017, 110: 51-61.
doi: S0928-0987(17)30043-X
pmid: 28115222
|
[10] |
MA F, YAN M, LI W, et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial[J]. BMJ, 2023, 383: e076065.
|
[11] |
CAO J, TENG Y E, LI H P, et al. Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial[J]. BMC Med, 2023, 21(1): 300.
doi: 10.1186/s12916-023-02999-0
pmid: 37559142
|
[12] |
JIANG K K, HONG R X, XIA W, et al. Pyrotinib combined with vinorelbine in patients with previously treated HER2-positive metastatic breast cancer: a multicenter, single-arm, prospective study[J]. Cancer Res Treat, 2023. Online ahead of print.
|
[13] |
HUA X, BI X W, ZHAO J L, et al. Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for patients with hormone receptor-positive and HER2-positive metastatic breast cancer (SYSUCC-002)[J]. Clin Cancer Res, 2022, 28(4): 637-645.
doi: 10.1158/1078-0432.CCR-21-3435
|
[14] |
HU Z Y, YAN M, XIONG H H, et al. Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase Ⅱ trial[J]. BMC Med, 2023, 21(1): 226.
doi: 10.1186/s12916-023-02943-2
|
[15] |
ZHANG J, MENG Y C, WANG B Y, et al. PLEASURABLE: results and biomarkers analysis from the phase Ⅱ study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC)[J]. J Clin Oncol, 2023, 41(16_suppl): 1046.
|
[16] |
BIANCHINI G, BALKO J M, MAYER I A, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease[J]. Nat Rev Clin Oncol, 2016, 13(11): 674-690.
doi: 10.1038/nrclinonc.2016.66
pmid: 27184417
|
[17] |
JIANG Y Z, MA D, SUO C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies[J]. Cancer Cell, 2019, 35(3): 428-440.e5.
doi: 10.1016/j.ccell.2019.02.001
|
[18] |
LIU Y, ZHU X Z, XIAO Y, et al. Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: the FUTURE phase Ⅱ umbrella clinical trial[J]. Cell Res, 2023, 33(5): 389-402.
doi: 10.1038/s41422-023-00795-2
|
[19] |
FAN L, WANG Z H, MA L X, et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial[J]. Lancet Oncol, 2024: S1470-S2045(23)00579-X.
|
[20] |
BURSTEIN H J, CURIGLIANO G, LOIBL S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen international consensus guidelines for the primary therapy of early breast cancer 2019[J]. Ann Oncol, 2019, 30(10): 1541-1557.
doi: S0923-7534(19)60978-6
pmid: 31987446
|
[21] |
SCHMID P, CORTES J, PUSZTAI L, et al. Pembrolizumab for early triple-negative breast cancer[J]. N Engl J Med, 2020, 382(9): 810-821.
doi: 10.1056/NEJMoa1910549
|
[22] |
MITTENDORF E A, ZHANG H, BARRIOS C H, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial[J]. Lancet, 2020, 396(10257): 1090-1100.
doi: 10.1016/S0140-6736(20)31953-X
pmid: 32966830
|
[23] |
LIU J Q, LIU Q, LI Y, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase Ⅱ trial[J]. J Immunother Cancer, 2020, 8(1): e000696.
doi: 10.1136/jitc-2020-000696
|
[24] |
CHEN L, JIANG Y Z, WU S Y, et al. Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-plus): an open-label, single-arm, phase Ⅱ trial[J]. Clin Cancer Res, 2022, 28(13): 2807-2817.
doi: 10.1158/1078-0432.CCR-21-4313
|
[25] |
WANG C Z, LIU Z Z, CHEN X C, et al. Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase Ⅱ trial[J]. Nat Commun, 2023, 14(1): 6654.
doi: 10.1038/s41467-023-42479-w
|
[26] |
JIANG Z F, OUYANG Q C, SUN T, et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial[J]. Nat Med, 2024, 30(1): 249-256.
doi: 10.1038/s41591-023-02677-x
pmid: 38191615
|
[27] |
GOLDENBERG D M, CARDILLO T M, GOVINDAN S V, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)[J]. Oncotarget, 2015, 6(26): 22496-22512.
pmid: 26101915
|
[28] |
BARDIA A, MAYER I A, VAHDAT L T, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med, 2019, 380(8): 741-751.
doi: 10.1056/NEJMoa1814213
|
[29] |
BARDIA A, TOLANEY S M, PUNIE K, et al. Biomarker analyses in the phase Ⅲ ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer[J]. Ann Oncol, 2021, 32(9): 1148-1156.
doi: 10.1016/j.annonc.2021.06.002
|
[30] |
XU B H, MA F, WANG T, et al. A phase Ⅱb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments[J]. Int J Cancer, 2023, 152(10): 2134-2144.
doi: 10.1002/ijc.v152.10
|
[31] |
WANG X G, FAN Z Q, WANG X, et al. Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study[J]. Breast Cancer Res Treat, 2022, 195(3): 301-310.
doi: 10.1007/s10549-022-06686-1
|
[32] |
BRAAL C L, JONGBLOED E M, WILTING S M, et al. Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences[J]. Drugs, 2021, 81(3): 317-331.
doi: 10.1007/s40265-020-01461-2
pmid: 33369721
|
[33] |
XU B H, ZHANG Q Y, ZHANG P, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial[J]. Nat Med, 2021, 27(11): 1904-1909.
doi: 10.1038/s41591-021-01562-9
pmid: 34737452
|
[34] |
ZHANG P, ZHANG Q Y, TONG Z S, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2023, 24(6): 646-657.
doi: 10.1016/S1470-2045(23)00172-9
|
[35] |
LIU M, XIE F, LIU M Y, et al. Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis[J]. Breast Cancer Res Treat, 2021, 186(3): 591-605.
doi: 10.1007/s10549-021-06104-y
|
[36] |
LITTON J K, RUGO H S, ETTL J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation[J]. N Engl J Med, 2018, 379(8): 753-763.
doi: 10.1056/NEJMoa1802905
|
[37] |
ROBSON M, IM S A, SENKUS E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J]. N Engl J Med, 2017, 377(6): 523-533.
doi: 10.1056/NEJMoa1706450
|
[38] |
XU B H, SUN T, SHI Y X, et al. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase Ⅱ study[J]. Breast Cancer Res Treat, 2023, 197(3): 489-501.
doi: 10.1007/s10549-022-06785-z
|
[39] |
邵志博, 杨犇龙, 吴炅. 2022年中国乳腺癌重要临床试验成果及最新进展[J]. 中国癌症杂志, 2023, 33(2): 103-109.
doi: 10.19401/j.cnki.1007-3639.2023.02.002
|
|
SHAO Zhibo, YANG Benlong, WU Jiong. Progress of important clinical trials of breast cancer in China in 2022[J]. China Oncology, 2023, 33(2): 103-109.
doi: 10.19401/j.cnki.1007-3639.2023.02.002
|